SNDX Earnings Prediction
The chart below shows how SNDX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SNDX sees a -3.37% change in stock price 10 days leading up to the earnings, and a -5.77% change 10 days following the report. On the earnings day itself, the stock moves by +0.71%. This data can give you a slight idea of what to expect for the next quarter's release.
SNDX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
12.50M
--
257.14%
Gross Margin
--
--
--
Operating Margin
-716.62%
--
-66.20%
Net Margin
-673.01%
--
-65.39%
EPS
-0.98
-34.25%
22.50%
No Data Available
SNDX Earnings Analysis
Syndax Pharmaceuticals, Inc. Corporation (SNDX.O) Earnings Conference Call
Positive
FDA Approval for Chronic GVHD: Niktimvo is now FDA-approved and included in the latest NCCN guidelines as a recommended treatment for chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kilograms.
New Medicine Availability Timeline: We anticipate that this new medicine will be available to patients no later than early in the first quarter of 2025.
Cash Position and Profitability: We expect the $399.6 million in cash, equivalents and short- and long-term investments on our balance sheet as of September 30, plus the $350 million in cash received from the royalty funding agreement for Niktimvo, will provide sufficient cash for Syndax to reach profitability.
Operating Expenses Breakdown: Operating expenses in the third quarter were $102.1 million and included $71 million of research and development expense and $31.1 million of selling, general and administrative expense.
Expense Guidance Update: For the full year 2024, the company is narrowing its guidance and now expects research and development expenses to be $245 million to $250 million and total expenses to be $365 million to $370 million.
Negative
Operating Expenses Breakdown: Operating expenses in the third quarter were $102.1 million and included $71 million of research and development expense and $31.1 million of selling, general and administrative expense.
Expense Guidance Update: For the full year 2024, the company is narrowing its guidance and now expects research and development expenses to be $245 million to $250 million and total expenses to be $365 million to $370 million.
Operating Expense Guidance: The guidance range for operating expense for the full year 2024 includes an estimated $41 million of non-cash stock compensation expense, which is down from our previously estimated $43 million, and that research and development expense guidance includes any milestones earned or expected to be earned by our partners upon potential approvals.
Cash Position and Profitability: We expect that the $399.6 million in cash, equivalents and short- and long-term investments on our balance sheet as of September 30, plus the $350 million in cash received from the royalty funding agreement for Niktimvo, will provide sufficient cash for Syndax to reach profitability, ensuring strong launches for revenue-generating Niktimvo and solidifying our commitment to their continued development and expansion of the pipeline overall.
Expense Guidance Update: The company is narrowing its guidance and now expects research and development expenses to be $245 million to $250 million and total expenses to be $365 million to $370 million.
SNDX FAQs
How does SNDX typically perform around its earnings report dates?
Is Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SNDX Earning Call Sentiment
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
SNDX.O
-0.28%Positive
The earnings call summary highlights a strong financial position, significant market opportunities, and strategic partnerships. Despite concerns in the Q&A about specific FDA data requirements, the overall sentiment is positive due to expected drug approvals, robust cash reserves, and a solid commercial strategy. The royalty agreement further strengthens financials, suggesting a positive stock price movement. Given the small-cap nature, this is likely to result in a 2% to 8% increase.